Share chart Biogen
Extended chart
Simple chart
About Biogen
Biogen Inc. — американская многонациональная биотехнологическая компания, базирующаяся в Кембридже, штат Массачусетс, специализирующаяся на открытии, разработке и поставке методов лечения нейродегенеративных, гематологических и аутоиммунных заболеваний пациентам во всем мире.IPO date | 1991-09-16 |
---|---|
ISIN | US09062X1037 |
Industry | Biotechnology |
Sector | Health Care |
Валюта | usd |
Валюта отчета | usd |
Див.доход ао | 0 |
Дивиденд ао | 22.23 |
Сайт | http://www.biogen.com |
Цена ао | 140.19 |
Change price per day: | 0% (140.19) |
---|---|
Change price per week: | -4.87% (147.37) |
Change price per month: | +0.5739% (139.39) |
Change price per 3 month: | -9.75% (155.33) |
Change price per half year: | -28.34% (195.63) |
Change price per year: | -36.17% (219.62) |
Change price per 3 year: | -36.7% (221.46) |
Change price per 5 year: | -42.86% (245.33) |
Change price per 10 year: | -41.4% (239.247) |
Change price per year to date: | -6.15% (149.38) |
|
Underestimation
|
Efficiency
|
|||||||||||||||||||||||||||||||||||||
Dividends
|
Debt
|
Growth impulse
|
Transaction date | Date of disclosure | Insider | Type | Price | Volume | Quantity | Share before, % | Share after, % | Document |
---|---|---|---|---|---|---|---|---|---|
07.02.2025 | 10.02.2025 | Gregory Ginger EVP, Human Resources |
Purchase | 142.54 | 489 767 | 3436 | 0 | 0 | link |
07.02.2025 | 10.02.2025 | ALEXANDER SUSAN H EVP Chief Legal Officer |
Purchase | 142.54 | 588 690 | 4130 | 0 | 0 | link |
31.01.2025 | 03.02.2025 | Singhal Priya Head of Development |
Purchase | 143.93 | 263 104 | 1828 | 0 | 0 | link |
12.02.2024 | 13.02.2024 | Singhal Priya Head of Development |
Sale | 239.45 | 100 330 | 419 | 0 | 0 | link |
09.02.2024 | 13.02.2024 | Izzar Rachid Head of Global Product Strat. |
Purchase | 226.53 | 343 193 | 1515 | 0 | 0 | link |
09.02.2024 | 13.02.2024 | Kramer Robin Chief Accounting Officer |
Purchase | 226.53 | 188 699 | 833 | 0 | 0 | link |
09.02.2024 | 13.02.2024 | MCDONNELL MICHAEL R EVP, Chief Financial Officer |
Purchase | 226.53 | 737 808 | 3257 | 0 | 0 | link |
09.02.2024 | 13.02.2024 | Murphy Nicole Head of Pharm Ops and Tech |
Purchase | 226.53 | 514 676 | 2272 | 0 | 0 | link |
09.02.2024 | 13.02.2024 | Singhal Priya Head of Development |
Purchase | 226.53 | 274 554 | 1212 | 0 | 0 | link |
09.02.2024 | 13.02.2024 | Gregory Ginger EVP, Human Resources |
Purchase | 226.53 | 488 852 | 2158 | 0 | 0 | link |
08.02.2024 | 09.02.2024 | Murphy Nicole Head of Pharm Ops and Tech |
Purchase | 240.58 | 505 459 | 2101 | 0 | 0 | link |
08.02.2024 | 09.02.2024 | MCDONNELL MICHAEL R EVP, Chief Financial Officer |
Purchase | 240.58 | 561 754 | 2335 | 0 | 0 | link |
08.02.2024 | 09.02.2024 | Kramer Robin Chief Accounting Officer |
Purchase | 240.58 | 189 577 | 788 | 0 | 0 | link |
08.02.2024 | 09.02.2024 | Izzar Rachid Head of Global Product Strat. |
Purchase | 240.58 | 491 505 | 2043 | 0 | 0 | link |
08.02.2024 | 09.02.2024 | Gregory Ginger EVP, Human Resources |
Purchase | 240.58 | 393 348 | 1635 | 0 | 0 | link |
08.02.2024 | 09.02.2024 | ALEXANDER SUSAN H EVP Chief Legal Officer |
Purchase | 240.58 | 526 870 | 2190 | 0 | 0 | link |
28.04.2023 | 02.05.2023 | Gregory Ginger EVP, Human Resources |
Sale | 300 | 804 300 | 2681 | 0 | 0 | link |
08.12.2022 | 12.12.2022 | Kramer Robin Chief Accounting Officer |
Purchase | 289.47 | 101 315 | 350 | 0 | 0 | link |
27.10.2022 | 28.10.2022 | ALEXANDER SUSAN H EVP Chief Legal Off & Corp Sec |
Sale | 280.7 | 1 552 830 | 5532 | 0 | 0 | link |
30.08.2022 | 31.08.2022 | BIOGEN INC. 10% Owner |
Sale | 5.27 | 527 000 | 100000 | 0 | -0.07 | link |
29.08.2022 | 31.08.2022 | BIOGEN INC. 10% Owner |
Sale | 5.33 | 2 132 000 | 400000 | 0 | -0.27 | link |
01.07.2022 | 06.07.2022 | Izzar Rachid Head of Alzheimer's Disease |
Purchase | 215.98 | 108 854 | 504 | 0 | 0 | link |
01.07.2022 | 06.07.2022 | Kramer Robin Chief Accounting Officer |
Purchase | 215.98 | 54 427 | 252 | 0 | 0 | link |
07.06.2021 | 09.06.2021 | Guindo Chirfi Head of Glob Prod Strat & Com |
Sale | 440 | 1 358 280 | 3087 | 0 | 0 | link |
07.06.2021 | 09.06.2021 | Sandrock Alfred Head of Research & Development |
Sale | 440 | 3 375 680 | 7672 | 0 | 0 | link |
04.06.2021 | 07.06.2021 | Posner Brian S Director |
Sale | 274.17 | 98 701 | 360 | 0 | 0 | link |
Institutions | Volume | Share, % |
---|---|---|
PRIMECAP Management Company | 16264481 | 11.19 |
Vanguard Group Inc | 14407330 | 9.91 |
Blackrock Inc. | 14246658 | 9.8 |
State Street Corporation | 6945665 | 4.78 |
T. Rowe Price Investment Management, Inc. | 5357326 | 3.69 |
Wellington Management Group, LLP | 5324396 | 3.66 |
JP Morgan Chase & Company | 5011319 | 3.45 |
Geode Capital Management, LLC | 3309317 | 2.28 |
Invesco Ltd. | 1814666 | 1.25 |
ClearBridge Investments, LLC | 1679302 | 1.16 |
Head | Job title | Payment | Year of birth |
---|---|---|---|
Ms. Robin C. Kramer | Senior VP & Chief Accounting Officer | N/A | 1966 (59 years) |
Ms. Natacha Gassenbach | Chief Communication Officer & Head of Corporate Affairs | N/A | |
Ms. Nicole Murphy | Head of Pharmaceutical Operations & Technology | 1.46M | 1973 (52 years) |
Mr. Michael R. McDonnell CPA | Executive VP & CFO | 2.12M | 1964 (61 year) |
Ms. Susan H. Alexander Esq. | Executive VP & Chief Legal Officer | 2.2M | 1957 (68 years) |
Mr. Christopher A. Viehbacher | President, CEO & Director | 487.94k | 1961 (64 years) |
Mr. Charles E. Triano | Senior VP & Head of Investor Relations | N/A | |
Mr. Adam Keeney Ph.D. | Executive VP & Head of Corporate Development | N/A | 1977 (48 years) |
Mr. Rachid Izzar | Head of Global Product Strategy & Commercialization | 1975 (50 years) | |
Dr. Ginger Gregory Ph.D. | Executive VP & Chief Human Resources Officer | 1968 (57 years) |
Address: United States, Cambridge, MA , 225 Binney Street - open in Google maps, open in Yandex maps
Website: http://www.biogen.com
Website: http://www.biogen.com